News

| Ari Fried
April 13th, 2018

Gornitzky represents the underwriters, led by Oppenheimer & Co., in Intec Pharma’s public offering.

Gornitzky represented the underwriters, led by Oppenheimer & Co., in the USD 37.5 million follow-on offering of Intec Pharma Ltd. on the NASDAQ Capital Market. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology.


Oppenheimer & Co. Inc. acted as sole book-running manager for the offering. Ladenburg Thalmann and Roth Capital Partners acted as co-managers for the offering.


The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner), Danielle Skald (Associate) and Nir Knoll (Associate).

January 23rd, 2018

Gornitzky represented the underwriters, led by Jefferies and Cowen and Company, in the USD 69 million follow-on offering of UroGen Pharma Ltd.

Gornitzky represented the underwriters, led by Jefferies and Cowen and Company, in the USD 69 million follow-on offering of UroGen Pharma Ltd. on the NASDAQ Global Market. UroGen Pharma is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology.

Jefferies and Cowen and Company acted as joint book-running managers for the offering. Oppenheimer & Co. acted as lead manager for the offering and Ladenburg Thalmann & Co. and National Securities Corporation acted as co-managers for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner).

 

November 13th, 2017

Gornitzky represents underwriters in RedHill Biopharma’s USD 22.5 million public offering.

Gornitzky represented the underwriters, led by Cantor Fitzgerald and Nomura Securities, in RedHill Biopharma’s USD 22.5 million underwritten public offering of American Depositary Shares (ADSs) on the NASDAQ Capital Market. RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer, is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: RDHL, TASE: RDHL).

 

Cantor Fitzgerald and Nomura Securities acted as joint book-running managers for the offering. SMBC Nikko Securities acted as lead manager and H.C. Wainwright and Roth Capital acted as co-managers for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Nir Knoll (Associate).

August 28th, 2017

Gornitzky represents the underwriters, led by Oppenheimer & Co., in Intec Pharma’s offering.

Gornitzky represented the underwriters, led by Oppenheimer & Co., in the USD 57.5 million follow-on offering of Intec Pharma Ltd. on the NASDAQ Capital Market. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology.

 

Oppenheimer & Co. Inc. acted as sole book-running manager for the offering. Roth Capital Partners acted as lead manager, and Maxim Group LLC acted as co-manager for the offering.

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner), Danielle Skald (Associate) and Nir Knoll (Associate).

May 11th, 2017

Gornitzky represented the underwriters, led by Jefferies and Cowen & Company, in the USD 67 million IPO of UroGen Pharma Ltd. on the NASDAQ Global Market.

Gornitzky represented the underwriters, led by Jefferies and Cowen & Company, in the USD 67 million IPO of UroGen Pharma Ltd. on the NASDAQ Global Market. UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology.

 

The IPO was the first major underwritten IPO of an Israeli company in the United States since 2015.

 

Jefferies and Cowen & Company acted as joint book-running managers for the offering. Raymond James & Associates and Oppenheimer & Co. acted as co-managers for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Sagit Amit Evan (Associate).

 

December 27th, 2016

Gornitzky represents the underwriters, led by Roth Capital, in RedHill Biopharma’s USD 39 million public offering and concurrent registered direct offering of its ADSs and warrants

Gornitzky represented the underwriters, led by Roth Capital Partners, in RedHill Biopharma’s USD 39 million underwritten public offering of American Depositary Shares (ADSs) and warrants on the NASDAQ Capital Market and concurrent registered direct offering of its ADSs and warrants. RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on drugs for inflammatory and gastrointestinal diseases and cancer, is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: RDHL, TASE: RDHL).

Roth Capital Partners acted as the sole book-running manager and Echelon Wealth Partners acted as Canadian manager for the underwritten public offering with respect to sales in Canada. Roth Capital Partners acted as placement agent in the registered direct offering.

 

See full story

The underwriters were represented by Chaim Friedland (Partner) and Ari Fried (Partner).

November 18th, 2015

Gornitzky represented the underwriters, led by Jefferies and Barclays, in Alcobra Ltd.’s USD 40 million offering of shares on the NASDAQ Global Market. 

Gornitzky represented the underwriters, led by Jefferies and Barclays, in Alcobra Ltd.’s USD 40 million offering of shares on the NASDAQ Global Market. Alcobra is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X

Syndrome (FXS).

 

Jefferies and Barclays acted as joint book-running managers for the offering. Oppenheimer, Roth Capital and Cantor Fitzgerald acted as co-managers for the offering

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Avi Meer.

July 22nd, 2015

Gornitzky represents the underwriters, led by Nomura and Roth Capital, in RedHill Biopharma’s USD 40 million public offering of ADSs

 

 

 

 

 

Gornitzky represented the underwriters, led by Nomura and Roth Capital Partners, in RedHill Biopharma’s USD 40 million public offering of American Depository Shares (ADSs) on the NASDAQ Capital Market. RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on drugs for inflammatory and gastrointestinal diseases, is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: RDHL, TASE: RDHL).

 

Nomura Securities and Roth Capital Partners acted as joint book-running managers for the offering. MLV & Co. and H.C. Wainwright acted as co-managers for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Sagit Amit Evan.

 

 

March 25th, 2015

Gornitzky & Co. represented the underwriters, led by Wells Fargo and RBC, in the USD 40 million initial public offering of SteadyMed Ltd. on the NASDAQ Global Market. 

Gornitzky & Co. represented the underwriters, led by Wells Fargo and RBC, in the USD 40 million initial public offering of SteadyMed Ltd. on the NASDAQ Global Market. SteadyMed is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs.

Wells Fargo Securities and RBC Capital Markets acted as joint book-running managers for the offering. JMP Securities acted as lead manager for the offering.

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Yoav Meer.

November 26th, 2014

Gornitzky represented Northland Capital Markets in the USD 10 million follow-on offering of On Track Innovations Ltd. (NASDAQ: OTIV) on the NASDAQ Global Market.

Gornitzky represented Northland Capital Markets in the USD 10 million follow-on offering of On Track Innovations Ltd. (NASDAQ: OTIV) on the NASDAQ Global Market.  Northland Securities acted as sole underwriter for the offering.

 

Northland Capital Markets, a boutique investment banking firm that focuses on growth companies and institutional investors, was represented by Chaim Friedland (Partner), Ari Fried (Partner) and Yoav Meer.

October 6th, 2014

Gornitzky represented the underwriters, led by Deutsche Bank, in the USD 40 million initial public offering of Vascular Biogenics Ltd. (operating as VBL Therapeutics) on the NASDAQ Global Market.

Gornitzky represented the underwriters, led by Deutsche Bank, in the USD 40 million initial public offering of Vascular Biogenics Ltd. (operating as VBL Therapeutics) on the NASDAQ Global Market.

 

Deutsche Bank acted as book-running manager for the offering. JMP Securities and Oppenheimer & Co. acted as co-managers for the offering.

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Yoav Meer.

April 2nd, 2014

Gornitzky represented Altria Group Inc. in its acquisition of Green Smoke Inc., an electronic cigarette business, for USD 110 million and up to USD 20 million in incentive payments.

Gornitzky represented Altria Group Inc. (NYSE: MO) in its acquisition of Green Smoke Inc., an electronic cigarette business, and its affiliates. Altria, which owns the top U.S. cigarette maker, Philip Morris USA, has purchased Green Smoke for USD 110 million and up to USD 20 million in incentive payments.

 

Altria Group Inc. was represented by Chaim Friedland (Partner, Corporate M&A), Yoram Arad (Partner, High-Tech), Ari Fried (Partner, Corporate M&A), Idan Baki (Partner, Finance), Michael Ayalon (Partner, Labor), Dafna Michalevich-Bacharach (High-Tech), Avi Meer (Corporate) and Joanna Yanowsky (Labor).

March 5th, 2014

Gornitzky & Co. represented the underwriters, led by Bank of America Merrill Lynch and Jefferies, in the USD 151 million secondary public offering of shares of Enzymotec Ltd. on the NASDAQ Global Select Market.


Gornitzky & Co. represented the underwriters, led by Bank of America Merrill Lynch and Jefferies, in the USD 151 million secondary public offering of shares of Enzymotec Ltd. on the NASDAQ Global Select Market.

 

Bank of America Merrill Lynch and Jefferies acted as joint book-running managers for the offering. Wells Fargo Securities acted as lead manager for the offering and Canaccord Genuity and Wedbush Securities acted as co-managers for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Yoav Meer.

March 4th, 2014

Gornitzky & Co. represented the underwriters, led by Goldman Sachs, Credit Suisse and Jefferies, in Lumenis Ltd.’s USD 75 million public offering on the NASDAQ Global Select Market.

Gornitzky & Co. represented the underwriters, led by Goldman Sachs, Credit Suisse and Jefferies, in Lumenis Ltd.’s USD 75 million public offering on the NASDAQ Global Select Market.

 

Goldman Sachs, Credit Suisse and Jefferies acted as joint book-running managers for the offering. Wells Fargo Securities acted as co-manager for the offering.


The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Sagit Amit Evan.

September 11th, 2013

Gornitzky represented Rutledge Vine Capital in its equity investment in Tok Media International Ltd., a private company in the social media space. 

Gornitzky represented Rutledge Vine Capital in its equity investment in Tok Media International Ltd., a private company in the social media space. Rutledge's investment in Tok Media is its second investment in the company following an investment earlier this year, where it was also represented by Gornitzky.

Rutledge Vine Capital is a global Super Angel Investor that provides early stage venture funding to startup and seed companies and technovation research projects across the globe.

Rutledge was represented by Ari Fried (Partner) and Yehonathan Raff.

 

June 9th, 2013

Gornitzky represented Rutledge Vine Capital in its second equity investment in Getonic Ltd., a private company which developed a social-shop platform. 

Gornitzky represented Rutledge Vine Capital in its second equity investment in Getonic Ltd., a private company which developed a social-shop platform. Rutledge's investment in Getonic is its second investment in the company following an investment made in mid-2012, where it was also represented by Gornitzky.

 

Rutledge Vine Capital is a global Super Angel Investor that provides early stage venture funding to startup and seed companies and technovation research projects across the world.

 

Rutledge was represented by Ari Fried (Partner).

April 18th, 2013

Gornitzky represented Tene Investment Funds, a private equity firm, in the USD 168 million sale of its holdings in Caesarstone Sdot-Yam Ltd. (Nasdaq: CSTE) in an underwritten follow-on offering. 

Gornitzky represented Tene Investment Funds, a private equity firm, in the USD 168 million sale of its holdings in Caesarstone Sdot-Yam Ltd. (Nasdaq: CSTE) in an underwritten follow-on offering.

 

J.P. Morgan Securities LLC, Barclays Capital Inc. and Credit Suisse Securities (USA) LLC served as the joint bookrunning managers for the offering, and Stifel, Nicolaus & Company, Incorporated and Robert W. Baird & Co. Incorporated served as the co-managers for the offering.

 

The representation of Tene Investment Funds was led by Chaim Friedland (Partner) and Ari Fried (Partner).

 

September 22nd, 2011

Gornitzky & Co. represented the underwriters, led by JPMorgan, Credit Suisse and Barclays, in the secondary public offering of Mellanox Technologies Ltd. on the NASDAQ.

Gornitzky & Co. represented the underwriters, led by JPMorgan, Credit Suisse and Barclays, in the secondary public offering of Mellanox Technologies Ltd. on the NASDAQ.

 

Mellanox Technologies Ltd., dually traded on the NASDAQ and the Tel Aviv Stock Exchange, conducted a secondary public offering of its shares on the NASDAQ in September 2011. The underwriters, led by JPMorgan, Credit Suisse and Barclays, were represented by Gornitzky & Co. and White & Case, LLP. The aggregate net proceeds from the offering were approximately USD 105 million, making it the second largest SPO of an Israeli company on the NASDAQ in 2011.

 

Gornitzky's representation of the underwriters was led by Mr. Chaim Friedland (Partner) and Mr. Ari Fried (Partner).

February 5th, 2018

Gornitzky represented the underwriters, led by Jefferies and BMO Capital Markets, in the USD 86 million IPO of Sol-Gel Technologies Ltd.

Gornitzky represented the underwriters, led by Jefferies and BMO Capital Markets, in the USD 86.3 million initial public offering of Sol-Gel Technologies Ltd. on the NASDAQ Global Market. Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.

 

Jefferies and BMO Capital Markets acted as joint book-running managers for the offering. JMP Securities and Raymond James acted as co-managers for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Yoav Meer (Associate).

 

November 21st, 2017

Gornitzky represents Piper Jaffray in VBL Therapeutics’ USD 18.75 million follow-on offering on NASDAQ.

Gornitzky represented Piper Jaffray in Vascular Biogenics Ltd.’s (operating as VBL Therapeutics) USD 18.75 million follow-on offering on the NASDAQ Global Market. VBL Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.

Piper Jaffray & Co. acted as the sole manager for the offering.

The underwriters were represented by Chaim Friedland (Partner) and Ari Fried (Partner).

October 1st, 2017

Gornitzky represents the underwriters, led by Cowen and Company and Wells Fargo, in MediWound’s follow-on offering on NASDAQ.

Gornitzky represented the underwriters, led by Cowen and Company and Wells Fargo Securities, in the USD 25 million follow-on offering of MediWound Ltd. on the NASDAQ Global Market. MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications.

 

Cowen and Company, LLC and Wells Fargo Securities, LLC acted as joint book-running managers for the offering. Oppenheimer & Co. Inc. and SunTrust Robinson Humphrey, Inc. acted as co-lead managers for the offering. Aegis Capital Corp. acted as a co-manager for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner), Sagit Amit Evan (Senior Associate), together with Associates Danielle Skald and Daniella Segal.

August 3rd, 2017

Gornitzky represents the underwriters, led by Cantor Fitzgerald, in Kamada's follow-on offering. 

Gornitzky represented the underwriters, led by Cantor Fitzgerald, in the USD 15 million follow-on offering of Kamada Ltd. on the NASDAQ Global Select Market. Kamada is a plasma-derived protein therapeutics company focused on orphan indications, and its shares are dually traded on the NASDAQ and the Tel Aviv Stock Exchange.

Cantor Fitzgerald acted as sole book-running manager for the offering. Raymond James, Oppenheimer & Co., Ladenburg Thalmann and Chardan acted as co-managers for the offering.

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner), Yoav Meer (Associate), Danielle Skald (Associate) and Sharon Strauss (Associate).

May 5th, 2017

Gornitzky represents Alcobra Ltd. in blocking an attempted hostile takeover.

A private investment fund, holding a certain amount of the company's shares, called for the immediate assembly of an extraordinary general meeting of shareholders, in order to remove the existing Directors and replace them with its own. Following Alcobra's refusal, based on legal advice provided by our firm, the investment fund chose to unilaterally summon an extraordinary general meeting during the month of May. Following our appeal to the Tel Aviv District Court for Economic Affairs, an injunction was issued, prohibiting the investment fund from sending out summons and proxies to the company's shareholders in Israel and abroad. At the end of the day, the sides reached an agreement, according to which it was agreed that the extraordinary general meeting of shareholders summoned by the investment fund shall be cancelled and the company shall convene its annual general meeting on July 20, 2017.

Alcobra Ltd. was represented by Kfir Yadgar (Managing Partner), Chaim Friedland (Partner), Ari Fried (Partner), Ofer Fleischer (Partner), together with Associates Shiran Knafo and Gil Palkovic

December 12th, 2016

Gornitzky represented the underwriters, led by Jefferies and Cowen and Company, in the USD 86 million follow-on offering of NeuroDerm Ltd. on the NASDAQ Global Market

Gornitzky represented the underwriters, led by Jefferies and Cowen and Company, in the USD 86 million follow-on offering of NeuroDerm Ltd. on the NASDAQ Global Market. NeuroDerm Ltd. is a clinical stage pharmaceutical company developing treatments for central nervous system (CNS) disorders.

Jefferies and Cowen and Company acted as joint book-running managers for the offering. Raymond James & Associates and Roth Capital Partners acted as co-managers for the offering.

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Nir Knoll.

November 11th, 2015

Gornitzky represented the underwriters, led by Piper Jaffray, in Vascular Biogenics Ltd.’s (operating as VBL Therapeutics) USD 15 million offering of shares and warrants on the NASDAQ Global Market. VBL Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.

Gornitzky represented the underwriters, led by Piper Jaffray, in Vascular Biogenics Ltd.’s (operating as VBL Therapeutics) USD 15 million offering of shares and warrants on the NASDAQ Global Market. VBL Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.

 

Piper Jaffray & Co. acted as sole bookrunner for the offering. JMP Securities acted as lead manager and Roth Capital Partners and LifeSci Capital acted as co-managers.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Yoav Meer.

 

July 21st, 2015

Gornitzky represented the underwriters, led by Jefferies and Cowen and Company, in NeuroDerm's USD 77 million follow-on offering on NASDAQ

 

 

Gornitzky represented the underwriters, led by Jefferies and Cowen and Company, in the USD 77 million follow-on offering of NeuroDerm Ltd. on the NASDAQ Global Market. NeuroDerm Ltd., is a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases.


Jefferies and Cowen and Company acted as joint book-running managers for the offering. Raymond James & Associates and Roth Capital Partners acted as co-managers for the offering.

  

The underwriters were represented by Chaim Friedland (Partner) and Ari Fried (Partner).

 

February 15th, 2015

Gornitzky & Co. represented the underwriters, led by Wells Fargo, in RedHill Biopharma’s USD 14.4 million public offering of American Depository Shares (ADSs) on the NASDAQ Capital Market.

Gornitzky & Co. represented the underwriters, led by Wells Fargo, in RedHill Biopharma’s USD 14.4 million public offering of American Depository Shares (ADSs) on the NASDAQ Capital Market. RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on drugs for inflammatory and gastrointestinal diseases, is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: RDHL, TASE: RDHL).

 

Wells Fargo Securities acted as lead book-running manager and Roth Capital Partners acted as joint book-running manager for the offering. MLV & Co acted as co-manager for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Sagit Amit Evan.


For more information on our capital markets practice, please click here.

November 19th, 2014

Gornitzky represented the underwriters, led by Jefferies and Cowen and Company, in the USD 45 million initial public offering of NeuroDerm Ltd. on the NASDAQ Global Market.

Gornitzky represented the underwriters, led by Jefferies and Cowen and Company, in the USD 45 million initial public offering of NeuroDerm Ltd. on the NASDAQ Global Market.


Jefferies and Cowen and Company acted as joint book-running managers for the offering. Oppenheimer & Co. and Roth Capital Partners acted as co-managers for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Yehonatan Raff.

August 5th, 2014

Gornitzky & Co. represented the underwriters, led by Credit Suisse and Jefferies in Macrocure Ltd.’s USD 53.5 million initial public offering on the NASDAQ Global Market.

Gornitzky & Co. represented the underwriters, led by Credit Suisse and Jefferies in Macrocure Ltd.’s USD 53.5 million initial public offering on the NASDAQ Global Market.

Credit Suisse and Jefferies acted as joint book-running managers for the offering. Nomura Securities and Oppenheimer & Co. acted as co-managers for the offering.

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Yoav Meer.

March 26th, 2014

Gornitzky & Co. represented the underwriters, led by Credit Suisse, Jefferies and BMO Capital Markets, in MediWound Ltd.’s USD 80.5 million initial public offering on the NASDAQ Global Market.


Gornitzky & Co. represented the underwriters, led by Credit Suisse, Jefferies and BMO Capital Markets, in MediWound Ltd.’s USD 80.5 million initial public offering on the NASDAQ Global Market.

 

Credit Suisse, Jefferies and BMO Capital Markets acted as joint book-running managers for the offering. Oppenheimer & Co. acted as co-manager for the offering.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Yoav Meer.

March 5th, 2014

Gornitzky & Co. represented the underwriters, led by Jefferies, in Compugen Ltd.’s USD 72.5 million public offering on the NASDAQ Global Market.


Gornitzky & Co. represented the underwriters, led by Jefferies, in Compugen Ltd.’s USD 72.5 million public offering on the NASDAQ Global Market. Compugen is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: CGEN, TASE: CGEN).

 

Jefferies LLC acted as the sole bookrunner for the offering.  JMP Securities, Oppenheimer & Co. and Chardan Capital Markets acted as co-managers.


The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Ariel Davis.

October 3rd, 2013

Gornitzky & Co. represented the underwriters, led by Bank of America Merrill Lynch and Jefferies, in the USD 71 million initial public offering of Enzymotec Ltd. on the NASDAQ Global Select Market.

Gornitzky & Co. represented the underwriters, led by Bank of America Merrill Lynch and Jefferies, in the USD 71 million initial public offering of Enzymotec Ltd. on the NASDAQ Global Select Market.

 

Bank of America Merrill Lynch and Jefferies LLC acted as joint book-running managers for the offering. Wells Fargo Securities, LLC acted as lead manager for the offering and Canaccord Genuity and Wedbush Securities acted as co-managers for the offering.

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Yoav Meer.

June 9th, 2013

Gornitzky represented Rutledge Vine Capital in its second equity investment in Getonic Ltd., a private company which developed a social-shop platform. 

Gornitzky represented Rutledge Vine Capital in its second equity investment in Getonic Ltd., a private company which developed a social-shop platform. Rutledge's investment in Getonic is its second investment in the company following an investment made in mid-2012, where it was also represented by Gornitzky.

 

Rutledge Vine Capital is a global Super Angel Investor that provides early stage venture funding to startup and seed companies and technovation research projects across the world.

 

Rutledge was represented by Ari Fried (Partner).

June 5th, 2013

Gornitzky & Co. represented the underwriters led by Morgan Stanley and Jefferies in the USD 59 million initial public offering of Kamada Ltd. on NASDAQ.

Gornitzky & Co. represented the underwriters, led by Morgan Stanley and Jefferies, in the USD 59 million initial public offering of Kamada Ltd. on the NASDAQ Global Select Market.

 

Kamada, a biopharmaceutical company engaged in specialty life-saving therapeutics, was traded on the Tel Aviv Stock Exchange prior to the NASDAQ offering and its shares are now traded on both the TASE and NASDAQ.

 

The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner) and Yoav Meer.

February 14th, 2013

Gornitzky represented Rutledge Vine Capital in its equity investment in Tok Media International Ltd., a private company in the social media space.

Gornitzky represented Rutledge Vine Capital in its equity investment in Tok Media International Ltd., a private company in the social media space. Rutledge's investment in Tok Media marks its fourth investment in Israel represented by Gornitzky.


Rutledge Vine Capital is a global Super Angel Investor that provides early stage venture funding to startup & seed companies and technovation research projects across the world.


Rutledge was represented by Mr. Ari Fried (Partner) and Mr. Yoav Meer.